Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health Prices $1B Senior Notes Offering

NEW YORK ─ Guardant Health said on Monday that it has priced a $1 billion private offering of 0 percent senior notes due in 2027, with an initial conversion rate of 7.1523 shares of common stock per $1,000 principal amount of notes — an initial conversion price of approximately $139.82 per share of common stock.

According to the company, this rate and conversion price will be subject to adjustment when certain events occur.

The initial purchasers have the option to buy additional notes up to a principal amount of $150,000,000 within a period of 13 days from the date the notes are first issued.

Guardant estimated its net proceeds will be approximately $984.3 million, or $1.13 billion if the initial buyers fully exercise their option.

The liquid biopsy firm intends to use $78.3 million of the net proceeds to fund the cost of entering into privately negotiated capped call transactions with one or more of the initial purchasers, respective affiliates, or other financial institutions. The remainder will support general corporate purposes and working capital.

The sale is scheduled to close on Nov. 19.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.